Besides IL‐10, we targeted the CXCR4/CXCL12 axis, due to its important role in stromal‐dependent resistance to therapy, further contributing to an immunosuppressive TME, which may impair CAR T‐cell function in CLL. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.